Ocular angiogenesis: translating preclinical indications to successful clinical development

Author： Konerding Moritz A  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.8, Iss.3, 2004-06, pp. : 255-258

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Positron Emitting Tracers in Pre-Clinical Drug Development

By  

Current Radiopharmaceuticals, Vol. 5, Iss. 2, 2012-04 ,pp. : 90-98

Bentham Science Publishers

Access to resources Recommend Favorite

TNP-470: an angiogenesis inhibitor in clinical development for cancer

By Kruger E.A.   Figg W.D.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 6, 2000-06 ,pp. : 1383-1396

Informa Healthcare

Access to resources Recommend Favorite

Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 11, 2015-11 ,pp. : 660-668

John Wiley & Sons Inc

Access to resources Recommend Favorite

Drugs in preclinical and early-stage clinical development for pancreatic cancer

By Asuthkar Swapna   Rao Jasti S   Gondi Christopher S  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 2, 2012-02 ,pp. : 143-152

Informa Healthcare

Access to resources Recommend Favorite

Application of Lipidomics to Assess Lipogenesis in Drug Development and Pre-Clinical Trials

By  

Current Pharmaceutical Biotechnology, Vol. 13, Iss. 5, 2012-04 ,pp. : 736-745

Bentham Science Publishers

Access to resources Recommend Favorite